

April 23, 2021

Q4FY21 Result Update

☑ Change in Estimates | ☑ Target | ■ Reco

Change in Estimates

	Cu	rrent	Previous			
	FY22E	FY23E	FY22E	FY23E		
Rating	E	BUY	В	UY		
Target Price	1	325	6	83		
Sales (Rs. m)	48,098	54,694	46,316	53,268		
% Chng.	3.8	2.7				
EBITDA (Rs. m)	7,912	8,979	7,265	8,021		
% Chng.	8.9	12.0				
EPS (Rs.)	44.3	51.6	40.5	45.6		
% Chng.	9.3	13.2				

Key Financials - Consolidated

Y/e Mar	FY20	FY21	FY22E	FY23E
Sales (Rs. m)	44,275	41,325	48,098	54,694
EBITDA (Rs. m)	5,959	6,060	7,912	8,979
Margin (%)	13.5	14.7	16.4	16.4
PAT (Rs. m)	3,707	3,743	4,973	5,794
EPS (Rs.)	33.0	33.4	44.3	51.6
Gr. (%)	(25.4)	1.0	32.9	16.5
DPS (Rs.)	11.8	11.9	15.8	18.4
Yield (%)	1.7	1.7	2.3	2.7
RoE (%)	14.5	14.0	17.0	17.9
RoCE (%)	14.0	13.5	17.4	18.8
EV/Sales (x)	1.6	1.7	1.4	1.2
EV/EBITDA (x)	11.7	11.3	8.5	7.5
PE (x)	20.8	20.6	15.5	13.3
P/BV (x)	3.0	2.7	2.5	2.2

Key Data	CYIE.BO CYL IN
52-W High / Low	Rs.710 / Rs.184
Sensex / Nifty	48,081 / 14,406
Market Cap	Rs.76bn/ \$ 1,011m
Shares Outstanding	110m
3M Avg. Daily Value	Rs.1237.44m

Shareholding Pattern (%)

Promoter's	23.47
Foreign	38.47
Domestic Institution	21.24
Public & Others	16.83
Promoter Pledge (Rs bn)	-

Stock Performance (%)

	1M	6M	12M
Absolute	1.9	61.7	220.6
Relative	5.7	36.9	104.3

Aniket Pande

aniketpande@plindia.com | 91-22-66322300

Aditi Patil

aditipatil@plindia.com |

Cyient (CYL IN)

Rating: BUY | CMP: Rs689 | TP: Rs825

Strong Showing continues...

Quick Pointers:

- Management guided double digit revenue growth for FY22 led by strong growth of 20% YoY in DLM and broad-based recovery from Services business.
- Management guided strong expansion of 200 bps YoY in EBIT margin for FY22. DLM margins are also expected to improve >200 bps YoY in FY22.
- Won 8 large deals with TCV potential of \$91 mn. Order-intake was robust in Q4 FY21 at \$238 Mn, +22.4% QoQ.

Cyient reported strong beat in revenue growth (+6% QoQ USD) led by strong demand momentum in DLM (+16.4% QoQ USD) and broad-based recovery in Services (+3.7% QoQ USD). They also reported robust 4QFY21 order book of \$238Mn, +22.4% QoQ and sustained strong large deal wins with TCV potential of \$91 Mn. As guided by the management, we believe that Cyient will report strong double digit growth in revenue in FY22 led by ramp up of deals won in FY21 and broad-based deal pipeline. They anticipate DLM to post robust growth of 20% YoY CC in FY22. Consolidated EBIT margin was at 8 quarter high at 12.6%, +148 bps QoQ in 4QFY21. Management guided that margins are expected to improve by 200 bps YoY in FY22 as headwinds of wage hike will be offset by automation, improvement in SG&A efficiency and niche digital capabilities to support pricing. Management has factored the potential supply side issues such as sharp increase in attrition (+800 bps QoQ in 4Q) in their guidance and will address these issues by appropriate wage hikes. Normal wage hike rollout for FY22 in 1HFY22 also indicates management's positive demand outlook.

We are increasing the multiple to 16X (earlier 15X, still at significant discount ~46.7% to LTTS) led by i) strong revenue growth momentum in DLM, iii) broad-based outlook on ER&D spends, iv) strong deal win momentum, v) scope to improve margins further and improved cash flow management with better payout. We have increased EPS estimates by 9.3%/13.2% for FY22/23E led by strong exit rate, broad-based revenue growth and guidance of ~200 bps margin expansion in FY22/23. We continue to stay ahead of cons estimates. We anticipate 13.7% revenue CAGR & 24.4% EPS CAGR for FY21-23E. We arrive at a TP of INR 825 (earlier INR 683) on FY23 EPS of INR 51.5. Cyient is currently trading at 15.6X/13.4X on FY22/23 earnings of INR 44.2/51.5 respectively. Maintain BUY.

Strong beat in revenue growth: Cyient reported revenue of \$149.9 Mn +6.0% QoQ USD (Ple:3%, Cons:1.6%), 3% above our estimates (Ple: \$145.6 Mn) led by higher than anticipated growth of +16.4% QoQ in DLM (\$30.3 Mn). DLM business reported strong growth of 28.3% YoY in FY21 led by strong demand from India (Make in India) and emerging markets to rebalance global supply chains. Services revenue growth of +3.7% QoQ was broad-based led by strong recovery in Semiconductor (+22.8% QoQ USD) and A&D (+3.9% QoQ USD) and strong demand momentum in E&U (+5.3% QoQ USD). Cyient management anticipates robust growth of 20% YoY in DLM business in FY22 led by i) Continued push for 'Make in India' to attract business moving out of China, ii) Increased electrification of vehicles, iii) increasing fuel prices and potential to attract new customers in Communication and Medical industries for new technologies

Cyient reported highest revenue in communications and semiconductor vertical in the last seven quarters.

Cyient continued its focus on customer-centricity to record the highest CSAT (Customer Satisfaction) score ever, driven by extending exceptional support to customers in challenging times. The company received multiple customer endorsements for delivery excellence from key customers, including Thales and Boeing

- Sustained strong deal win momentum: Order intake continued to grow at strong rate of 22.4% QoQ to \$238Mn. Order intake comprise of deal TCV recognized in purchase order book. Cyient also won 8 large deals with total contract potential of \$ 91 million. These include i) 6 large deals in Services worth \$71 million and ii) 2 large deals in DLM worth \$20 million. Cyient has invested in sales teams with focus on winning large deals and they will continue to invest to strengthen their digital portfolio.
- Strong growth guidance for FY22: Management expects double digit growth in FY22 led by deals expected to ramp up in FY22 and strong demand momentum in DLM and broad-based services demand recovery. FY22 revenue guidance for FY22 is 20% led by volume growth and increase in share of engineering/design as compared to manufacturing. They also mentioned that group revenue will decline in 1QFY22 due to drop in DLM, while Services revenue will witness growth on a sequential basis in Q1. The growth guidance also factors in potential supply side issues.
- Consistent improvement in EBIT margins since past three quarters: Consolidated EBIT margin was highest in last 8 quarters at 12.6% (Ple: 11.7%); +148 bps QoQ. Services EBIT at 13.6%; was up by 233 bps QoQ driven by improvement in operational metrics (209 bps), revenue growth leverage (96 bps) partly offset by net increase in SG&A (71 bps). DLM margins at 8.8%, down by 181 bps QoQ primarily due to higher proportion of revenues from India/Israel. Wage hike for FY22 will be rolled out in 1HFY22.
- Management anticipates sharp improvement in FY22 EBIT margin: Management mentioned that tailwinds from automation, SG&A efficiency improvements, curing of non-profitable accounts and improved revenue mix will offset headwinds from wage hike and improve margins in FY22 by ~200bps. Despite the headwind of wage hikes, management expects margins to be stable and improve in Q1 (roughly by 50 bps). They anticipate DLM margin to drop in Q1 due to lower volume and mix change but improvement YoY in FY22 by ~200 bps.
- Cyient to face supply side issues given sharp increase in attrition: Attrition jumped to 21.2%, +800bps QoQ led by intense competition and demand for talent. Total number of employees were lower by 155 this quarter. Management mentioned that they aim to reduce attrition through wage hike.
- Vertical wise outlook:

Aerospace & Defense (34.1% of revs, +10.6% QoQ, -9.9% YoY): Strong sequential growth was led by sustained strong demand from DLM business and growth in some key services accounts. Management mentioned that commercial aviation will report slow recovery in FY22 with larger part of growth in 2HFY22. They are investing in digital and automation which will translate to increased deal wins in coming quarters.

Communications (23.3% of revs, +2.5% QoQ, +3.8% YoY): Cyient won 6 major deals in FY21 in the areas of fiber, wireless, system integration and 5G rollout from existing and new clients and they continue to benefit from accelerated deployment of 5G networks which are now about 10% of revenue for this segment. Management's outlook remains positive in this segment and

In communication vertical, Cyient won 6 key deals in the areas of fiber, wireless, system integration and 5G rollout from existing and new clients in FY21. They continue to benefit from accelerated deployment of 5G networks which form ~10% of the revenue portfolio for this segment

Cyient retained its leadership position in engineering and R&D services for the seventh consecutive year, in the annual ratings by Zinnov, a leading global management and strategy consulting firm. they have invested strategically to strengthen their capabilities in digital network transformation.

Transportation (11.0% of revs, 0.8% QoQ, +8.4% YoY): Sequential growth was led by rail transportation, recovery of key accounts and ramp up of new engagements initiated in 2020. Overall, the industry is seeing increased infrastructure projects funneling demand across the engineering segment.

E&U (12.2% of revs, +8.5% QoQ, 2.5% YoY): On the mining and natural resources side, customers are increasingly re-inventing their operating models to suit the post-pandemic scenarios. Management's outlook remains positive with accelerated digital transformation supported by expectation of easing geopolitical situations in the South China sea and pandemic situation not worsening in Australia, Africa as well as North and South America. Utilities too witnessed a strong quarter and Cyient has a robust deal pipeline which provides good growth visibility for FY22.

Medical Technology and Healthcare (6.5% of revs, -2.5% QoQ, 56.3% YoY): The QoQ de-growth was due the supply chain issues which impacted one of the top DLM clients. Management's outlook for this sector for FY22 remains positive as they expect ramp-up of recently awarded contracts while strengthening their pipeline focused on digital transformation, embedded software and DLM services.

Semiconductor (5% of revs, 22.8% QoQ, 39% YoY): Customer demand for engineering services is expected to remain strong. Solutions is expected to recover gradually, though there is a risk of specific delays in projects due to deferred investment decisions.

Lower decline in FY21 led by strong momentum in DLM: Consolidated revenue for FY21 is at \$556.8 Mn; de-growth of 10.9% \$ (12.0%in CC). Services revenue at \$461.3 Mn; de-grew by 16.2% (17.7%in CC) whereas DLM revenue at \$95.6 Mn; grew by 28.3%YoY.


- FY21 Normalized EBIT margin excluding exceptional items is at 10.1%; up by 85 bps YoY. DSO improved considerably by 20 days in FY21 and by 7 days in 4QFY21. Improvement in cash flow management resulted in FCF conversion of 113.5% on EBITDA and conversion of 204.8% on PAT. Free Cash Flow generation at INR 7,609 Mn in FY21 was highest ever.
- Cyient reported exceptional loss of INR 79 mn due to impairment of goodwill of a European semiconductor asset, decrease in fair value of minority investments partially offset by reversal of earn-outs on past acquisitions due to one off lower performance for the year.
- Change in board composition: B V R Mohan Reddy, Founder and Executive Chairman of Cyient, has stepped down from the executive role and will continue to guide through the role of non-executive director. M M Murugappan, who has been on the Cyient's board as an independent director since 1997, has been appointed as the non-executive chairman. Board also appointed Ajay Aggarwal, CFO and Karthik Natarajan COO as Executive Director.

Exhibit 1: Q4FY21: Quick View on Results

Rs mn	4QFY21	3QFY21	QoQ (%)	4QFY20	YoY (%)	PL Estimates	Variance (Actual vs Ple)
Revenues (USD mn)	150	141	6.0%	149	0.5%	146	2.9%
Revenues (INR mn)	10,932	10,443	4.7%	10,736	1.8%	10,618	3.0%
EBITDA	1,874	1,650	13.6%	1,382	35.6%	1,720	9.0%
EBITDA Margins	17.1%	15.8%	134 bps	12.9%	427 bps	16.2%	94 bps
EBIT	1,383	1,165	18.7%	904	53.0%	1,242	11.3%
EBIT Margins	12.7%	11.2%	150 bps	8.4%	423 bps	11.7%	95 bps
Adjusted PAT	1,033	954	8.2%	451	129.0%	1,069	-3.4%
EPS	9	9	8.2%	4.0	134.9%	10	-3.4%


Source: Company, PL






Source: Company, PL





Source: Company, PL





Source: Company, PL





Exhibit 5: Consistent strong revenue growth in DLM business

Source: Company, PL

Exhibit 6: Sharp improvement in services EBITDA margin




Source: Company, PL

Client concentration further reduces

P





Source: Company, PL

Exhibit 8: Geography-wise revenues

USD in Mn	4QFY21	3QFY21	QoQ gr.	4QFY20	YoY gr.
America	71	69	2.3%	83	-16.5%
Europe, ME, Africa & India	37	36	3.1%	38	-6.7%
APAC	42	36	15.9%	28	30.4%
Total	150	141	6.0%	149	-5.2%
as a % of total					
America	47.4	49.1	-170 bps	55.7	-830 bps
Europe, ME, Africa & India	24.6	25.3	-70 bps	25.7	-110 bps
APAC	28.0	25.6	240 bps	18.6	940 bps

Source: Company, PL

Exhibit 9: Vertical-wise revenues

USD in Mn	4QFY21	3QFY21	QoQ gr.	4QFY20	YoY gr.
Aerospace and Defense	51.1	46.1	10.9%	56.4	-18.3%
Transportation	16.5	16.3	1.4%	15.2	6.9%
I&ENR	18.3	16.8	8.7%	17.9	-6.0%
Semiconductor	7.5	6.1	23.3%	5.4	13.2%
Medical & Healthcare	9.7	10.0	-2.9%	6.3	60.2%
Communications	34.9	34.1	2.5%	33.7	1.1%
Portfolio	12.0	11.9	1.0%	14.2	-16.2%
Total	150.0	141.3	6.2%	149.1	0.7%
as a % of total					
Aerospace and Defense	34.1	32.6	150 bps	37.8	-370 bps
Transportation	11.0	11.5	-50 bps	10.2	80 bps
I&ENR	12.2	11.9	30 bps	12	20 bps
Semiconductor	5.0	4.3	70 bps	3.6	140 bps
Medical & Healthcare	6.5	7.1	-60 bps	4.2	230 bps
Communications	23.3	24.1	-80 bps	22.6	70 bps
Portfolio	8.0	8.4	-40 bps	9.5	-150 bps

Source: Company, PL

Exhibit 10: Client Metrics

Client Buckets	4QFY18	1QFY19	2QFY19	3QFY19	4QFY19	1QFY20	2QFY20	3QFY20	4QFY20	1QFY21	2QFY21	3QFY21	4QFY21
20mn+	4	4	4	4	4	4	4	4	4	3	3	3	3
10mn+	12	11	13	13	13	12	12	11	11	9	7	7	8
5 mn+	24	25	31	31	29	28	27	27	26	30	32	32	30
1mn+	63	66	81	87	86	85	91	90	95	92	95	94	90

Source: Company, PL

Exhibit 11: Geography-wise revenue contribution (%)

Geographical Mix in %	1QFY19	2QFY19	3QFY19	4QFY19	1QFY20	2QFY20	3QFY20	4QFY20	1QFY21	2QFY21	3QFY21	4QFY21
North America	52.5	52.0	54.1	54.0	55.4	55.3	56.8	55.7	52.3	49.9	49.1	47.4
Europe	24.6	23.8	22.1	24.7	28.1	26.5	25.1	25.7	24.0	28.9	25.3	24.6
APAC	23.0	24.3	23.8	21.3	16.4	18.2	18.1	18.6	23.7	21.2	25.6	28.0

Source: Company, PL

Financials

Income Statement (Rs m)

income otatement (its in)				
Y/e Mar	FY20	FY21	FY22E	FY23E
Net Revenues	44,275	41,325	48,098	54,694
YoY gr. (%)	(4.1)	(6.7)	16.4	13.7
Employee Cost	24,537	21,805	25,124	28,725
Gross Profit	19,738	19,520	22,974	25,969
Margin (%)	44.6	47.2	47.8	47.5
SG&A Expenses	13,779	13,460	15,063	16,990
Other Expenses	-	-	-	-
EBITDA	5,959	6,060	7,912	8,979
YoY gr. (%)	(7.5)	1.7	30.6	13.5
Margin (%)	13.5	14.7	16.4	16.4
Depreciation and Amortization	1,878	1,944	2,164	2,188
EBIT	4,081	4,116	5,747	6,792
Margin (%)	9.2	10.0	11.9	12.4
Net Interest	517	472	216	216
Other Income	1,250	1,166	950	1,000
Profit Before Tax	4,814	4,810	6,481	7,576
Margin (%)	10.9	11.6	13.5	13.9
Total Tax	1,076	1,133	1,620	1,894
Effective tax rate (%)	22.4	23.6	25.0	25.0
Profit after tax	3,738	3,677	4,861	5,682
Minority interest	-	-	-	-
Share Profit from Associate	(31)	66	112	112
Adjusted PAT	3,707	3,743	4,973	5,794
YoY gr. (%)	(24.2)	1.0	32.9	16.5
Margin (%)	8.4	9.1	10.3	10.6
Extra Ord. Income / (Exp)	-	-	-	-
Reported PAT	3,707	3,743	4,973	5,794
YoY gr. (%)	(24.2)	1.0	32.9	16.5
Margin (%)	8.4	9.1	10.3	10.6
Other Comprehensive Income	-	-	-	-
Total Comprehensive Income	3,707	3,743	4,973	5,794
Equity Shares O/s (m)	110	110	110	110
EPS (Rs)	33.0	33.4	44.3	51.6

Balance Sheet Abstract (Rs m)

Y/e Mar	FY20	FY21	FY22E	FY23E
Non-Current Assets	1120			
Gross Block	15,616	18,616	21,616	25,616
Tangibles	10,033	12,433	14,533	17,333
Intangibles	5,583	6,183	7,083	8,283
Acc: Dep / Amortization	10,644	12,588	14,752	16,940
Tangibles	5,828	6,897	8,088	9,291
Intangibles	4,816	5,691	6,665	7,649
Net fixed assets	4,972	6,028	6,864	8,676
Tangibles	4,205	5,536	6,445	8,042
Intangibles	767	492	418	634
,				
Capital Work In Progress	4,163	4,163	4,163	4,163
Goodwill	5,374	5,374	5,374	5,374
Non-Current Investments	723	943	1,163	1,383
Net Deferred tax assets	18	18	18	18
Other Non-Current Assets	1,519	1,519	1,519	1,519
Current Assets				
Investments	-	100	200	300
Inventories	2,267	2,267	2,267	2,267
Trade receivables	7,262	7,359	8,565	9,740
Cash & Bank Balance	9,518	10,772	12,226	12,284
Other Current Assets	1,192	1,212	1,232	1,252
Total Assets	41,797	44,544	48,380	51,765
Equity				
Equity Share Capital	550	550	550	550
Other Equity	25,059	27,225	30,102	33,454
Total Networth	25,609	27,775	30,652	34,004
Non-Current Liabilities				
Long Term borrowings	859	859	859	859
Provisions	1,151	1,251	1,351	1,451
Other non current liabilities	24	24	24	24
	24	24	27	24
Current Liabilities				
ST Debt / Current of LT Debt	2,879	2,879	2,879	2,879
Trade payables	3,729	4,079	4,807	4,609
Other current liabilities	4,527	4,658	4,788	4,918
Total Equity & Liabilities	41,797	44,544	48,380	51,765

Source: Company Data, PL Research

P

Cash Flow (Rs m)

Y/e Mar	FY20	FY21	FY22E	FY23E
РВТ	4,783	4,876	6,593	7,688
Add. Depreciation	1,878	1,944	2,164	2,188
Add. Interest	517	472	216	216
Less Financial Other Income	1,250	1,166	950	1,000
Add. Other	(1,250)	(1,166)	(950)	(1,000)
Op. profit before WC changes	5,928	6,126	8,024	9,091
Net Changes-WC	1,257	443	(288)	(1,182)
Direct tax	(1,076)	(1,133)	(1,620)	(1,894)
Net cash from Op. activities	6,109	5,436	6,116	6,015
Capital expenditures	(5,567)	(3,000)	(3,000)	(4,000)
Interest / Dividend Income	1,250	1,166	950	1,000
Others	(38)	(300)	(300)	(300)
Net Cash from Invt. activities	(4,355)	(2,134)	(2,350)	(3,300)
Issue of share cap. / premium	-	-	-	-
Debt changes	485	-	-	-
Dividend paid	(1,562)	(1,577)	(2,096)	(2,441)
Interest paid	(517)	(472)	(216)	(216)
Others	1,953	1	-	-
Net cash from Fin. activities	359	(2,048)	(2,312)	(2,657)
Net change in cash	2,113	1,254	1,454	58
Free Cash Flow	542	2,436	3,116	2,015
Source: Company Data, PL Resea	rch			

Y/e Mar	FY20	FY21	FY22E	FY23E
Per Share(Rs)				
EPS	33.0	33.4	44.3	51.6
CEPS	50.8	51.7	64.9	72.6
BVPS	232.8	252.5	278.7	309.1
FCF	4.9	22.1	28.3	18.3
DPS	11.8	11.9	15.8	18.4
Return Ratio(%)				
RoCE	14.0	13.5	17.4	18.8
ROIC	16.0	15.2	19.6	20.2
RoE	14.5	14.0	17.0	17.9
Balance Sheet				
Net Debt : Equity (x)	(0.2)	(0.3)	(0.3)	(0.3)
Debtor (Days)	60	65	65	65
Valuation(x)				
PER	20.8	20.6	15.5	13.3
P/B	3.0	2.7	2.5	2.2
P/CEPS	13.6	13.3	10.6	9.5
EV/EBITDA	11.7	11.3	8.5	7.5
EV/Sales	1.6	1.7	1.4	1.2
Dividend Yield (%)	1.7	1.7	2.3	2.7

Source: Company Data, PL Research

Quarterly Financials (Rs m)

Y/e Mar	Q1FY21	Q2FY21	Q3FY21	Q4FY21
Net Revenue	9,917	10,033	10,443	10,932
YoY gr. (%)	(8.9)	(13.4)	(5.6)	1.8
Raw Material Expenses	5,825	5,375	5,507	5,430
Gross Profit	4,092	4,658	4,936	5,502
Margin (%)	41.3	46.4	47.3	50.3
EBITDA	947	1,589	1,650	1,874
YoY gr. (%)	(34.5)	(0.6)	7.6	35.6
Margin (%)	9.5	15.8	15.8	17.1
Depreciation / Depletion	484	484	485	491
EBIT	463	1,105	1,165	1,383
Margin (%)	4.7	11.0	11.2	12.7
Net Interest	100	107	136	129
Other Income	684	93	219	170
Profit before Tax	1,047	1,091	1,248	1,348
Margin (%)	10.6	10.9	12.0	12.3
Total Tax	272	252	294	315
Effective tax rate (%)	26.0	23.1	23.6	23.4
Profit after Tax	775	839	954	1,033
Minority interest	-	-	-	-
Share Profit from Associates	38	28	-	-
Adjusted PAT	813	867	954	1,033
YoY gr. (%)	(9.4)	(11.0)	(11.9)	129.0
Margin (%)	8.2	8.6	9.1	9.4
Extra Ord. Income / (Exp)	-	-	-	-
Reported PAT	813	867	954	1,033
YoY gr. (%)	(9.4)	(11.0)	(11.9)	129.0
Margin (%)	8.2	8.6	9.1	9.4
Other Comprehensive Income	-	-	-	-
Total Comprehensive Income	813	867	954	1,033
Avg. Shares O/s (m)	113	114	110	110
EPS (Rs)	7.2	7.6	8.7	9.4

April 23, 2021

Cyient

Cyient

Price Chart



Date	Rating	TP (Rs.) Share Pi	rice (Rs.)
05-Apr-21	BUY	683	666
22-Jan-21	BUY	681	508
04-Jan-21	BUY	606	514
22-Dec-20	BUY	584	491
23-Nov-20	BUY	492	485
05-Oct-20	BUY	456	379
01-Oct-20	BUY	456	384
02-Sep-20	BUY	431	387
	05-Apr-21 22-Jan-21 04-Jan-21 22-Dec-20 23-Nov-20 05-Oct-20 01-Oct-20	05-Apr-21 BUY 22-Jan-21 BUY 04-Jan-21 BUY 22-Dec-20 BUY 23-Nov-20 BUY 05-Oct-20 BUY 01-Oct-20 BUY	05-Apr-21 BUY 683 22-Jan-21 BUY 681 04-Jan-21 BUY 606 22-Dec-20 BUY 584 23-Nov-20 BUY 492 05-Oct-20 BUY 456 01-Oct-20 BUY 456

Recommendation History

Analyst Coverage Universe

Sr. No.	Company Name	Rating	TP (Rs)	Share Price (Rs)
1	Coforge	BUY	3,020	2,924
2	Cyient	BUY	683	666
3	HCL Technologies	BUY	1,168	1,001
4	Infosys	BUY	1,632	1,397
5	L&T Technology Services	BUY	3,006	2,721
6	Larsen & Toubro Infotech	BUY	4,394	4,121
7	Mindtree	BUY	2,567	2,070
8	Mphasis	BUY	1,869	1,749
9	Persistent Systems	BUY	2,017	1,954
10	Redington (India)	BUY	189	184
11	Sonata Software	BUY	537	522
12	Tata Consultancy Services	BUY	3,636	3,247
13	TeamLease Services	BUY	4,002	3,774
14	Tech Mahindra	BUY	1,143	990
15	Wipro	BUY	500	431
16	Zensar Technologies	BUY	290	276

PL's Recommendation Nomenclature (Absolute Performance)

Buy	:	> 15%
Accumulate	:	5% to 15%
Hold	:	+5% to -5%
Reduce	:	-5% to -15%
Sell	:	< -15%
Not Rated (NR)	:	No specific call on the stock
Under Review (UR)	:	Rating likely to change shortly

ANALYST CERTIFICATION

(Indian Clients)

We/l, Mr. Aniket Pande- MBA, Ms. Aditi Patil- MBA Finance Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

(US Clients)

The research analysts, with respect to each issuer and its securities covered by them in this research report, certify that: All of the views expressed in this research report accurately reflect his or her or their personal views about all of the issuers and their securities; and No part of his or her or their compensation was, is or will be directly related to the specific recommendation or views expressed in this research report.

DISCLAIMER

Indian Clients

Prabhudas Lilladher Pvt. Ltd, Mumbai, India (hereinafter referred to as "PL") is engaged in the business of Stock Broking, Portfolio Manager, Depository Participant and distribution for third party financial products. PL is a subsidiary of Prabhudas Lilladher Advisory Services Pvt Ltd. which has its various subsidiaries engaged in business of commodity broking, investment banking, financial services (margin funding) and distribution of third party financial/other products, details in respect of which are available at www.plindia.com.

This document has been prepared by the Research Division of PL and is meant for use by the recipient only as information and is not for circulation. This document is not to be reported or copied or made available to others without prior permission of PL. It should not be considered or taken as an offer to sell or a solicitation to buy or sell any security.

The information contained in this report has been obtained from sources that are considered to be reliable. However, PL has not independently verified the accuracy or completeness of the same. Neither PL nor any of its affiliates, its directors or its employees accepts any responsibility of whatsoever nature for the information, statements and opinion given, made available or expressed herein or for any omission therein.

Recipients of this report should be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The suitability or otherwise of any investments will depend upon the recipient's particular circumstances and, in case of doubt, advice should be sought from an independent expert/advisor.

Either PL or its affiliates or its directors or its employees or its representatives or its clients or their relatives may have position(s), make market, act as principal or engage in transactions of securities of companies referred to in this report and they may have used the research material prior to publication.

PL may from time to time solicit or perform investment banking or other services for any company mentioned in this document.

PL is in the process of applying for certificate of registration as Research Analyst under Securities and Exchange Board of India (Research Analysts) Regulations, 2014

PL submits that no material disciplinary action has been taken on us by any Regulatory Authority impacting Equity Research Analysis activities.

PL or its research analysts or its associates or his relatives do not have any financial interest in the subject company.

PL or its research analysts or its associates or his relatives do not have actual/beneficial ownership of one per cent or more securities of the subject company at the end of the month immediately preceding the date of publication of the research report.

PL or its research analysts or its associates or his relatives do not have any material conflict of interest at the time of publication of the research report.

PL or its associates might have received compensation from the subject company in the past twelve months

PL or its associates might have managed or co-managed public offering of securities for the subject company in the past twelve months or mandated by the subject company for any other assignment in the past twelve months.

PL or its associates might have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months.

PL or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months

PL or its associates might have received any compensation or other benefits from the subject company or third party in connection with the research report.

PL encourages independence in research report preparation and strives to minimize conflict in preparation of research report. PL or its analysts did not receive any compensation or other benefits from the subject Company or third party in connection with the preparation of the research report. PL or its Research Analysts do not have any material conflict of interest at the time of publication of this report.

It is confirmed that Mr. Aniket Pande- MBA, Ms. Aditi Patil- MBA Finance Research Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

The Research analysts for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

The research analysts for this report has not served as an officer, director or employee of the subject company PL or its research analysts have not engaged in market making activity for the subject company

Our sales people, traders, and other professionals or affiliates may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest.

PL and its associates, their directors and employees may (a) from time to time, have a long or short position in, and buy or sell the securities of the subject company or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company or act as an advisor or lender/borrower to the subject company or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.

US Clients

This research report is a product of Prabhudas Lilladher Pvt. Ltd., which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by Prabhudas Lilladher Pvt. Ltd. only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor.

In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, Prabhudas Lilladher Pvt. Ltd. has entered into an agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo").

Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

Prabhudas Lilladher Pvt. Ltd.

3rd Floor, Sadhana House, 570, P. B. Marg, Worli, Mumbai-400 018, India | Tel: (91 22) 6632 2222 Fax: (91 22) 6632 2209 www.plindia.com